S&P Futures
4,171.00 -20.50 (-0.49%) Dow Futures
34,114.00 +17.00 (+0.05%) Nasdaq Futures
12,667.00 -179.75 (-1.40%) Russell 2000 Futures
2,007.60 -0.30 (-0.01%) Crude Oil
75.66 -0.22 (-0.29%) Gold
1,928.20 -2.60 (-0.13%)
ZIVO Bioscience, Inc. (ZIVO)
Chart Events
Performance Outlook
| Previous Close | 3.4600 |
| Open | 3.4900 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1400 |
| Day's Range | 3.1700 - 3.4900 |
| 52 Week Range | 2.1600 - 4.6000 |
| Volume | |
| Avg. Volume | 8,783 |
| Market Cap | 31.462M |
| Beta (5Y Monthly) | 0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0220 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business
BLOOMFIELD HILLS, Mich., October 24, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generati
- Business Wire
ZIVO Bioscience CEO Issues Letter to Shareholders
BLOOMFIELD HILLS, Mich., September 23, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
- Business Wire
ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment
BLOOMFIELD HILLS, Mich., August 10, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces receipt of a letter from the U.S. Department of Agriculture’s (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company’s novel immune-modulating biologic for treating cocc
